Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513848 | 1.00 | GABBR2 (0.50) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL8972871 | 1.00 | GABBR2 (0.50) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL6513856 | 1.00 | GABBR2 (0.50) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL8973181 | 1.00 | GABBR2 (0.50) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL8973184 | 1.00 | GABBR2 (0.50) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL8972865 | 1.00 | GABBR2 (0.50) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL27984377 | 0.83 | CYP1A2 (0.47) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL10723686 | 0.82 | GABBR2 (0.44) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL10723695 | 0.82 | GABBR2 (0.44) | GABBR2GABRB1GABRB2GABBR1CYP1A2 | |
| SCHEMBL7021780 | 0.79 | GABRB2 (0.50) | GABBR2GABRB1GABRB2GABBR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3062885-A | — | — | None | — | — | JP | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022086840-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20210388007-A1 | COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | WUHAN UNIVERSITY (CN) | 2021-12-16 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| WO-2021150806-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-0566485-B1 | Process for producing optically active halogen-containing alcohol | SHOWA SHELL SEKIYU (JP) | 1999-07-14 | — | — | EP | disclosed |
| US-5464772-A | Process for producing optically active halogen-containing alcohols using lipase ay-120 from Candida rugosa | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1995-11-07 | — | — | US | disclosed |
| EP-0566485-A2 | Process for producing optically active halogen-containing alcohol | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1993-10-20 | — | — | EP | disclosed |
| JP-H0362885-A | OPTICALLY ACTIVE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL ELEMENT CONTAINING THE SAME | SHARP CORP | 1991-03-18 | — | — | JP | disclosed |
| US-4701569-A | PERFLUOROALKYLATION OF CARBONYL COMPOUNDS IN PRESENCE OF ZINC IN ABSENCE OF ULTRASONIC WAVES | RHONE-POULENC SPECIALTIES CHIMIQUES (FR) | 1987-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | GABBR2 3104/4885GABRB1 3523/4885GABRB2 3795/4885 |
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | GABBR2 3104/4885GABRB1 3523/4885GABRB2 3795/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | GABBR2 3104/4885GABRB1 3523/4885GABRB2 3795/4885 |
| US-20210388007-A1 | COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | CYP2F1, CYP4F3, CFH | GABBR2 1166/4885GABRB1 2284/4885GABRB2 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.